Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.76 |
| ▸ | JAK2 | O60674 | 13/20 | 0.76 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.76 |
| ▸ | JAK3 | P52333 | 12/20 | 0.76 |
| ▸ | IKBKB | O14920 | 8/20 | 0.68 |
| ▸ | JAK1 | P23458 | 5/20 | 0.68 |
| ▸ | TYK2 | P29597 | 5/20 | 0.68 |
| ▸ | NAMPT | P43490 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.60 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12465048 | 1.00 | ROCK2 (0.76) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL25478352 | 1.00 | ROCK2 (0.76) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL3613021 | 1.00 | ROCK2 (0.76) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL2163450 | 1.00 | ROCK2 (0.76) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL20353563 | 0.93 | ROCK2 (0.69) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL20353560 | 0.92 | JAK2 (0.70) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL20525021 | 0.90 | ROCK2 (0.69) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL20524964 | 0.90 | ROCK2 (0.69) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL22752104 | 0.89 | ROCK2 (0.68) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL21774943 | 0.89 | ROCK2 (0.63) | ROCK2JAK2ROCK1JAK3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899714-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160280656-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2016-09-29 | — | — | US | disclosed |
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280656-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | ROCK2 246/4885JAK2 616/4885ROCK1 375/4885 |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | ROCK2 246/4885JAK2 616/4885ROCK1 375/4885 |
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | ROCK2 246/4885JAK2 616/4885ROCK1 375/4885 |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | ROCK2 246/4885JAK2 616/4885ROCK1 375/4885 |
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | ROCK2 246/4885JAK2 616/4885ROCK1 375/4885 |
| US-10899714-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | ROCK2 246/4885JAK2 616/4885ROCK1 375/4885 |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | ROCK2 246/4885JAK2 616/4885ROCK1 375/4885 |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | ROCK2 246/4885JAK2 616/4885ROCK1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.